Eli Lilly's latest full results from its three-year SURMOUNT-1 trial show tirzepatide significantly reduces the risk of progression to Type 2 diabetes in prediabetic adults who are obese or overweight. The trial demonstrated a 94% reduced risk of developing Type 2 diabetes versus placebo, with nearly 99% of patients remaining diabetes-free over the 176-week treatment period. The highest dose of 15 mg supported an average weight loss of 22.9%, and lower doses also sustained significant reductions. Even after a 17-week off-treatment period, only 2.4% of patients on tirzepatide developed Type 2 diabetes, compared to 13.7% in the placebo group.

Tirzepatide, marketed as Mounjaro for Type 2 diabetes and Zepbound for obesity, also showed improvements in glycemic control, cardiometabolic risk factors, and quality of life measures. Safety data were consistent with previous findings, predominantly showing mild-to-moderate gastrointestinal side effects.

The promising results come amid mixed third-quarter results for Lilly, although executives remain confident, citing ongoing investments and international expansion to drive growth.

For more information, visit Fierce Pharma.